Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer - Top-Institutions - MDSpire

Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.

  • June 24, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, New York

    Key Differentiators

    • Oncology

  • #2

    Moffitt Cancer Center and Research Institute
    Moffitt Cancer Center and Research Institute

    Tampa, Florida

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering
    Memorial Sloan Kettering

    New York, New York

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer

  • June 24, 2026

Related Content

Troponin for surveillance of immune checkpoint inhibitor–associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis

Adrenal tumor microenvironment: hormone–immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities

Editorial: Novel insights into CAR T-cell associated neurotoxicity, volume II